Targeting alterations in both the PI3K-AKT-mTOR and DNA repairs pathways has shown synergy in preclinical studies. Here, the authors a phase I/II clinical trial investigating the combination of Olaparib (PARP inhibitor), metronomic cyclophosphamide (chemotherapy) and metformin (PI3K-AKT-mTOR inhibitor) in patients with recurrent endometrial carcinoma.
- Max Piffoux
- Alexandra Leary
- Benoit You
